https://www.selleckchem.com/pr....oducts/gusacitinib.h
ospital stay, length of surgery, and intraoperative blood loss). We are conducting the trial to explore the metastasis-positive rate of intraoperative restaging strategy for diagnosing pancreatic cancer micro-metastasis. This new intraoperative restaging strategy would help pancreatic cancer patients with potential micro-metastasis avoid receiving unnecessary resection, allow systemic treatment as early as possible, and improve the prognosis of patients. We are conducting the trial to explore the metastasis-positive rate of intraope
Like
Comment
Share
